Cargando…

Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy

BACKGROUND: To report a case of orbital inflammation after bisphosphonate infusion in a patient who was already receiving immunosuppressive therapy. CASE PRESENTATION: A 56-year-old woman presented to the ophthalmology clinic with acute onset of right eye pain 24 h after receiving her first Zolendro...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera, Isabella, Kam, Yong, Whittaker, Thomas J., Champion, Mary, Ajlan, Radwan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374910/
https://www.ncbi.nlm.nih.gov/pubmed/30764790
http://dx.doi.org/10.1186/s12886-019-1063-8
_version_ 1783395261937090560
author Herrera, Isabella
Kam, Yong
Whittaker, Thomas J.
Champion, Mary
Ajlan, Radwan S.
author_facet Herrera, Isabella
Kam, Yong
Whittaker, Thomas J.
Champion, Mary
Ajlan, Radwan S.
author_sort Herrera, Isabella
collection PubMed
description BACKGROUND: To report a case of orbital inflammation after bisphosphonate infusion in a patient who was already receiving immunosuppressive therapy. CASE PRESENTATION: A 56-year-old woman presented to the ophthalmology clinic with acute onset of right eye pain 24 h after receiving her first Zolendronic acid infusion. She has a past medical history of chronic inflammatory demyelinating polyneuropathy, Sjogren’s syndrome, and systemic lupus erythematosus that have been controlled with immunosuppressive therapy for three years. Clinical ophthalmic exam and MRI studies were significant for right orbital inflammation. The patient was started on oral prednisone with rapid resolution of symptoms. CONCLUSIONS: This is the first case report of a patient receiving chronic immunosuppressive therapy to develop orbital inflammation after Zoledronic acid infusion. In addition, it demonstrates that corticosteroids can be an effective first line therapy in treating orbital inflammation in similar patients. Physicians should be aware of this rare but serious potential side effect of bisphosphonates, and have bisphosphonate-related orbital inflammation on their differential for proper initiation of treatment.
format Online
Article
Text
id pubmed-6374910
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63749102019-02-26 Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy Herrera, Isabella Kam, Yong Whittaker, Thomas J. Champion, Mary Ajlan, Radwan S. BMC Ophthalmol Case Report BACKGROUND: To report a case of orbital inflammation after bisphosphonate infusion in a patient who was already receiving immunosuppressive therapy. CASE PRESENTATION: A 56-year-old woman presented to the ophthalmology clinic with acute onset of right eye pain 24 h after receiving her first Zolendronic acid infusion. She has a past medical history of chronic inflammatory demyelinating polyneuropathy, Sjogren’s syndrome, and systemic lupus erythematosus that have been controlled with immunosuppressive therapy for three years. Clinical ophthalmic exam and MRI studies were significant for right orbital inflammation. The patient was started on oral prednisone with rapid resolution of symptoms. CONCLUSIONS: This is the first case report of a patient receiving chronic immunosuppressive therapy to develop orbital inflammation after Zoledronic acid infusion. In addition, it demonstrates that corticosteroids can be an effective first line therapy in treating orbital inflammation in similar patients. Physicians should be aware of this rare but serious potential side effect of bisphosphonates, and have bisphosphonate-related orbital inflammation on their differential for proper initiation of treatment. BioMed Central 2019-02-14 /pmc/articles/PMC6374910/ /pubmed/30764790 http://dx.doi.org/10.1186/s12886-019-1063-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Herrera, Isabella
Kam, Yong
Whittaker, Thomas J.
Champion, Mary
Ajlan, Radwan S.
Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy
title Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy
title_full Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy
title_fullStr Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy
title_full_unstemmed Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy
title_short Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy
title_sort bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374910/
https://www.ncbi.nlm.nih.gov/pubmed/30764790
http://dx.doi.org/10.1186/s12886-019-1063-8
work_keys_str_mv AT herreraisabella bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy
AT kamyong bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy
AT whittakerthomasj bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy
AT championmary bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy
AT ajlanradwans bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy